Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Eloxx Pharmaceuticals Inc's Business Segments
Eloxx Pharmaceuticals Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
2
Largest Segment
License and Service
Total Revenue
-
Regions Reported
-
Revenue Share by Reportable Segment - FY
- License and Service0%
- Member0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| License and Service | - | - |
| Member | - | - |
Annual Results
Revenue Share by Reportable Segment - FY
- License and Service0%
- Member0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| License and Service | - | - |
| Member | - | - |
Description of Eloxx Pharmaceuticals Inc
Eloxx Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company that focuses on the discovery and development of novel therapeutics for the treatment of rare and ultra-rare genetic diseases caused by nonsense mutations. Founded in 2013 and headquartered in Waltham, Massachusetts, Eloxx Pharmaceuticals is dedicated to improving the lives of patients with rare diseases through innovative and targeted drug development.
The company's pipeline is centered around its proprietary drug discovery and development platform, which leverages advanced technologies and expertise in RNA biology. Eloxx Pharmaceuticals utilizes a highly selective and precise approach to identify and validate potential drug candidates that can selectively restore proper protein production in cells affected by nonsense mutations.
One of Eloxx Pharmaceuticals' lead drug candidates is ELX-02, a small molecule drug designed to treat genetic diseases caused by nonsense mutations. These mutations result in premature termination of protein synthesis, leading to the production of non-functional or truncated proteins. ELX-02 promotes readthrough of the nonsense codons, allowing the synthesis of full-length and functional proteins. This innovative approach has the potential to address the underlying cause of various rare diseases and offer therapeutic options where none currently exist.
Eloxx Pharmaceuticals conducts rigorous preclinical and clinical studies to evaluate the safety, efficacy, and pharmacokinetic properties of its drug candidates. The company collaborates with leading academic institutions, research organizations, and patient advocacy groups to advance its scientific understanding and ensure its therapies meet the needs of patients.
In addition to its primary focus on genetic diseases caused by nonsense mutations, Eloxx Pharmaceuticals also explores potential applications of its platform technology in other genetic disorders. The company actively pursues strategic partnerships and collaborations to expand the reach of its drug candidates and maximize their potential impact on patient care.
Overall, Eloxx Pharmaceuticals Inc. is a biopharmaceutical company at the forefront of developing innovative therapies for rare genetic diseases. Through its proprietary platform and commitment to scientific excellence, the company aims to bring novel treatments to patients in need, making a significant difference in their lives and the broader rare disease community.
The company's pipeline is centered around its proprietary drug discovery and development platform, which leverages advanced technologies and expertise in RNA biology. Eloxx Pharmaceuticals utilizes a highly selective and precise approach to identify and validate potential drug candidates that can selectively restore proper protein production in cells affected by nonsense mutations.
One of Eloxx Pharmaceuticals' lead drug candidates is ELX-02, a small molecule drug designed to treat genetic diseases caused by nonsense mutations. These mutations result in premature termination of protein synthesis, leading to the production of non-functional or truncated proteins. ELX-02 promotes readthrough of the nonsense codons, allowing the synthesis of full-length and functional proteins. This innovative approach has the potential to address the underlying cause of various rare diseases and offer therapeutic options where none currently exist.
Eloxx Pharmaceuticals conducts rigorous preclinical and clinical studies to evaluate the safety, efficacy, and pharmacokinetic properties of its drug candidates. The company collaborates with leading academic institutions, research organizations, and patient advocacy groups to advance its scientific understanding and ensure its therapies meet the needs of patients.
In addition to its primary focus on genetic diseases caused by nonsense mutations, Eloxx Pharmaceuticals also explores potential applications of its platform technology in other genetic disorders. The company actively pursues strategic partnerships and collaborations to expand the reach of its drug candidates and maximize their potential impact on patient care.
Overall, Eloxx Pharmaceuticals Inc. is a biopharmaceutical company at the forefront of developing innovative therapies for rare genetic diseases. Through its proprietary platform and commitment to scientific excellence, the company aims to bring novel treatments to patients in need, making a significant difference in their lives and the broader rare disease community.
Eloxx Pharmaceuticals Inc. is a pioneering biopharmaceutical company dedicated to developing innovative therapeutics specifically aimed at addressing the unmet medical needs of patients suffering from rare and ultra-rare genetic diseases, particularly those caused by nonsense mutations in their genetic code. These types of mutations lead to the production of non-functional proteins, which can severely impact health and quality of life. By focusing on these unique genetic challenges, Eloxx aims to develop targeted treatments that can fundamentally alter the disease progression and improve patient outcomes.
Segments
Eloxx Pharmaceuticals primarily operates within the biopharmaceutical segment, with a concentrated focus on genetic therapies. This segment comprises several interrelated areas:
1. Research and Development (R&D): This is the backbone of Eloxx Pharmaceuticals, where groundbreaking research is conducted to understand the mechanisms of rare genetic diseases and develop novel therapeutic approaches.
2. Clinical Development: The company undertakes rigorous clinical trials to evaluate the safety and efficacy of its product candidates, ensuring comprehensive data is collected to support regulatory submissions.
3. Regulatory Affairs: Eloxx engages with various regulatory bodies (like the FDA and EMA) to secure approval for the investigational drugs, navigating the complex regulatory landscape to ensure compliance and expedite the product journey from laboratory to market.
4. Commercialization: Once approved, Eloxx Pharmaceuticals works towards bringing its therapies to market, ensuring that healthcare providers and patients are informed and have access to these critical treatments.
5. Patient Support: Understanding the challenges faced by patients with rare diseases, Eloxx may offer specialized programs designed to educate patients and their families about the diseases and the available treatment options, fostering a supportive community.
Products
Eloxx Pharmaceuticals boasts a promising pipeline of therapeutics intended to treat various rare genetic diseases, with a main focus on products designed to target nonsense mutations. Here are some key elements of their product portfolio:
1. ELX-02: This is the flagship product candidate under development for the treatment of cystic fibrosis (CF) associated with nonsense mutations. ELX-02 is designed as a precision medicine that aims to bypass the faulty genetic information, thereby restoring the production of functional proteins in cells. This has the potential to enhance lung function, reduce the frequency of pulmonary infections, and overall, improve the quality of life for patients suffering from this devastating condition.
2. Pipeline Expansion: Besides ELX-02, Eloxx Pharmaceuticals is exploring additional therapeutic candidates aimed at treating other conditions linked to nonsense mutations. These include:
- Rett Syndrome: A rare genetic disorder that predominantly affects females and results in severe cognitive and physical impairments. Eloxx is investigating potential therapies that can address the underlying mechanisms of this disorder.
- Usher Syndrome: A condition that results in hearing loss and vision impairment, where Eloxx aims to develop treatments that can restore or improve sensory function.
3. Pre-Clinical Candidates: The company is also in the process of identifying and optimizing other product candidates in pre-clinical stages which may target a broader range of genetic diseases, leveraging their proprietary technology and expertise in gene therapy.
Services
In addition to its developmental pursuits, Eloxx Pharmaceuticals offers a suite of services designed to enhance the efficiency of its operations and support the broader biopharmaceutical ecosystem:
1. Clinical Trial Management: Eloxx manages complex clinical trials by coordinating logistics, patient recruitment, site management, and regulatory compliance to streamline the research process.
2. Regulatory Affairs: The company provides expertise in navigating the regulatory landscape, ensuring that all trials and product submissions adhere to stringent guidelines set by health authorities.
3. Manufacturing and Supply Chain Management: Eloxx ensures that its product candidates are manufactured to the highest quality standards. The company manages the logistics of supplying its therapeutics, ensuring timely delivery for clinical trials and eventual commercial use.
4. Marketing and Sales: Upon successful approval of its drugs, Eloxx employs targeted marketing strategies to promote its products, raising awareness among healthcare providers and patients about treatment options.
5. Post-Marketing Surveillance: After product launch, the company remains committed to monitoring the performance of its therapies in real-world settings to ensure ongoing safety and efficacy, gathering valuable data that can inform future R&D initiatives.
In summary, Eloxx Pharmaceuticals Inc. operates at the forefront of biopharmaceutical innovation, focusing on the development and commercialization of therapies for rare genetic diseases caused by nonsense mutations. With a robust pipeline led by ELX-02 for cystic fibrosis and a commitment to expanding its offerings in related areas, Eloxx is positioned as a key player in addressing one of the most challenging segments of healthcare. Its comprehensive service offerings further underline its dedication to bringing effective treatments to patients in need.
Segments
Eloxx Pharmaceuticals primarily operates within the biopharmaceutical segment, with a concentrated focus on genetic therapies. This segment comprises several interrelated areas:
1. Research and Development (R&D): This is the backbone of Eloxx Pharmaceuticals, where groundbreaking research is conducted to understand the mechanisms of rare genetic diseases and develop novel therapeutic approaches.
2. Clinical Development: The company undertakes rigorous clinical trials to evaluate the safety and efficacy of its product candidates, ensuring comprehensive data is collected to support regulatory submissions.
3. Regulatory Affairs: Eloxx engages with various regulatory bodies (like the FDA and EMA) to secure approval for the investigational drugs, navigating the complex regulatory landscape to ensure compliance and expedite the product journey from laboratory to market.
4. Commercialization: Once approved, Eloxx Pharmaceuticals works towards bringing its therapies to market, ensuring that healthcare providers and patients are informed and have access to these critical treatments.
5. Patient Support: Understanding the challenges faced by patients with rare diseases, Eloxx may offer specialized programs designed to educate patients and their families about the diseases and the available treatment options, fostering a supportive community.
Products
Eloxx Pharmaceuticals boasts a promising pipeline of therapeutics intended to treat various rare genetic diseases, with a main focus on products designed to target nonsense mutations. Here are some key elements of their product portfolio:
1. ELX-02: This is the flagship product candidate under development for the treatment of cystic fibrosis (CF) associated with nonsense mutations. ELX-02 is designed as a precision medicine that aims to bypass the faulty genetic information, thereby restoring the production of functional proteins in cells. This has the potential to enhance lung function, reduce the frequency of pulmonary infections, and overall, improve the quality of life for patients suffering from this devastating condition.
2. Pipeline Expansion: Besides ELX-02, Eloxx Pharmaceuticals is exploring additional therapeutic candidates aimed at treating other conditions linked to nonsense mutations. These include:
- Rett Syndrome: A rare genetic disorder that predominantly affects females and results in severe cognitive and physical impairments. Eloxx is investigating potential therapies that can address the underlying mechanisms of this disorder.
- Usher Syndrome: A condition that results in hearing loss and vision impairment, where Eloxx aims to develop treatments that can restore or improve sensory function.
3. Pre-Clinical Candidates: The company is also in the process of identifying and optimizing other product candidates in pre-clinical stages which may target a broader range of genetic diseases, leveraging their proprietary technology and expertise in gene therapy.
Services
In addition to its developmental pursuits, Eloxx Pharmaceuticals offers a suite of services designed to enhance the efficiency of its operations and support the broader biopharmaceutical ecosystem:
1. Clinical Trial Management: Eloxx manages complex clinical trials by coordinating logistics, patient recruitment, site management, and regulatory compliance to streamline the research process.
2. Regulatory Affairs: The company provides expertise in navigating the regulatory landscape, ensuring that all trials and product submissions adhere to stringent guidelines set by health authorities.
3. Manufacturing and Supply Chain Management: Eloxx ensures that its product candidates are manufactured to the highest quality standards. The company manages the logistics of supplying its therapeutics, ensuring timely delivery for clinical trials and eventual commercial use.
4. Marketing and Sales: Upon successful approval of its drugs, Eloxx employs targeted marketing strategies to promote its products, raising awareness among healthcare providers and patients about treatment options.
5. Post-Marketing Surveillance: After product launch, the company remains committed to monitoring the performance of its therapies in real-world settings to ensure ongoing safety and efficacy, gathering valuable data that can inform future R&D initiatives.
In summary, Eloxx Pharmaceuticals Inc. operates at the forefront of biopharmaceutical innovation, focusing on the development and commercialization of therapies for rare genetic diseases caused by nonsense mutations. With a robust pipeline led by ELX-02 for cystic fibrosis and a commitment to expanding its offerings in related areas, Eloxx is positioned as a key player in addressing one of the most challenging segments of healthcare. Its comprehensive service offerings further underline its dedication to bringing effective treatments to patients in need.